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Multiple pterygium syndromes (MPS) comprise a group of multiple congenital anomaly disorders characterized by webbing (pterygia) of
the neck, elbows, and/or knees and joint contractures (arthrogryposis). MPS are phenotypically and genetically heterogeneous but are
traditionally divided into prenatally lethal and nonlethal (Escobar) types. Previously, we and others reported that recessive mutations in
the embryonal acetylcholine receptor g subunit (CHRNG) can cause both lethal and nonlethal MPS, thus demonstrating that pterygia
resulted from fetal akinesia. We hypothesized that mutations in acetylcholine receptor-related genes might also result in a MPS/fetal aki-
nesia phenotype and so we analyzed 15 cases of lethal MPS/fetal akinesia without CHRNG mutations for mutations in the CHRNA1,
CHRNB1, CHRND, and rapsyn (RAPSN) genes. No CHRNA1, CHRNB1, or CHRND mutations were detected, but a homozygous RAPSN
frameshift mutation, c.1177-1178delAA, was identiﬁed in a family with three children affected with lethal fetal akinesia sequence.
Previously, RAPSN mutations have been reported in congenital myasthenia. Functional studies were consistent with the hypothesis
that whereas incomplete loss of rapsyn function may cause congenital myasthenia, more severe loss of function can result in a lethal
fetal akinesia phenotype.Multiple pterygia are found infrequently in children with
arthrogryposis and in fetuses with fetal akinesia syn-
drome.1 Autosomal-recessive inheritance ismost common,
but autosomal-dominant and X-linked inheritance has
been described. Lethal multiple pterygium syndrome
(LMPS [MIM 253290]) is an autosomal-recessively in-
herited disorder characterized by intrauterine growth retar-
dation, multiple pterygia and ﬂexion contractures causing
severe arthrogryposis, and fetal akinesia. In severe cases,
subcutaneous edema may be severe, causing fetal hydrops
with cystic hygroma and lung hypoplasia. Developmental
defects including cleft palate, cryptorchidism, intestinal
malrotation, cardiac hypoplasia, diaphragmatic hernia,
obstructive uropathy, microcephaly, or cerebellar and pon-
tine hypoplasia can also be present.2,3 The etiology of MPS
is heterogeneous. In a few cases, a diagnosis of a speciﬁc
primarymyopathy, metabolic, or neurodevelopmental dis-
order is made, but until recently, in many cases the under-
lying etiology was unknown.4 Recently, defects in the em-
bryonal acetylcholine receptor (AChR) were discovered to
account for a signiﬁcant proportion of patients with lethal
MPS and fetal akinesia. Thus, mutations in the acetylcho-
line receptor g subunit gene (CHRNG) were detected in ap-
proximately 30% of lethal MPS cases, and also in nonlethal
Escobar variant MPS.5,6 The nicotinic AChR of skeletal
muscle is a pentameric transmembrane protein composed
of four different subunits and exists in two forms. The
adult form is predominant in innervated adult muscle
and the embryonic form predominates in fetal and dener-222 The American Journal of Human Genetics 82, 222–227, Januaryvated muscle. The embryonic AChR consists of two alpha
and one each beta, gamma, and delta subunit (a2bdg),
whereas in the adult AChR, the gamma subunit is replaced
by an epsilon subunit (a2bd3).
7,8 In humans, the switch
from g to 3 occurs during fetal life and is apparently com-
plete by 31 weeks gestation (in rodents the switch occurs
postnatally).9–11 The identiﬁcation of CHRNG mutations
in MPS patients suggested that pterygia resulted from
early-onset fetal akinesia. Although the embryonal AChR
has a key role in normal prenatal muscle development,
the g subunit is not required postnatally and so Escobar
variant MPS patients did not demonstrate marked muscle
weakness.6 Mutations in other AChR subunits (except
CHRNE) would be predicted to produce both pre- and post-
natal neuromuscular transmission deﬁcits, and we specu-
lated that mutations in genes implicated in embryonal
AChR function might cause fetal akinesia and pterygia in
patients without CHRNGmutations.6 In addition, because
we have found that intrafamilial phenotypic variation in
kindreds with CHRNG mutations such that some affected
children had fetal akinesia without detectable pterygia,
we also included patients referred for CHRNG mutation
analysis without pterygia.
Mutation analysis of CHRNGwas undertaken in patients
with MPS and/or fetal akinesia as described previously
(unpublished data).6 Fifteen probands with no evidence
of a germline CHRNG mutation were then selected for
mutation analysis of the coding sequence and ﬂanking
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RAPSN. The clinical features of the 15 families are summa-
rized in Table 1.
DNAwas extracted andmutation analysis was performed
by standard methods and conditions (details of primer se-
quences available on request). No pathogenic mutations
were detected in CHRNA1, CHRNB1, or CHRND. However,
aRAPSN frameshiftmutationwas detected in a consanguin-
eous family with three affected children (see Figure 1). Both
parents were heterozygous, and all three affected children
were homozygous, for a c.1177-1178delAA mutation (see
Figure 1). The family presented when fetal akinesia se-
quence was detected at 19 weeks gestation in twin male
fetuses. On ultrasound examination, both fetuses had mi-
crognathia and ﬁxed position of the hands, elbows, and
feet. There were no respiratory movements, the thorax ap-
peared small, and there was mild hydrops. The pregnancy
was terminated at 23weeks of gestation. Postmortemexam-
Table 1. Clinical Features of 15 Fetuses Analyzed
Family ID Ethnic Origin Parental Consanguinity Phenotype
MPS013 Pakistani yes LMPS
MPS012 Bengali yes AMC, no pterygia
MPS014 white no LMPS
MPS016 white no LMPS
MPS017 white no LMPS
MPS018 white no LMPS
MPS019 Indian yes LMPS
MPS020 white no LMPS
MPS021 white no LMPS
MPS022 Afrikaner no LMPS
MPS023 white no LMPS
MPS010 Pakistani yes AMC, no pterygia
MPS009 Pakistani yes LMPS
MPS024 Palestinian yes LMPS
MPS025 Ethiopian no LMPS
LMPS, lethal multiple pterygium syndrome.The Amination revealed monochorionic, monoamniotic twins
with no evidence of growth retardation (twin 1, 0.587 kg
[~50 percentile]; twin 2, 0.665 kg [>50 percentile]). Both
twins had a ﬂat facial proﬁle, hypertelorism, moderate mi-
crognathia, and a short broad neck. They also hadmild hy-
drops with hydrothoraces and subcutaneous edema of the
head, neck, back of the shoulders, and proximal extremities
(Figures 2A and 2B). The lungs were hypoplastic and the di-
aphragm was thin and membranous. Both twins displayed
anabnormal posture,withhyperextensionat thewrists and
ﬂexion of the ﬁngers. Ankles were ﬁxed in a varus position
and the toes were hyperextended. No pterygia were de-
tected. Macroscopic and microscopic examination of the
brain showed no abnormality. Muscle histopathology re-
vealed muscle ﬁbers of varying diameters (considered to
be normal for the gestational age) with a normal striated
pattern and no ﬁbrosis. Chromosome analysis was normal
and molecular testing for congenital myotonic dystrophy
was negative. The couple went on to have another similarly
affected female singleton pregnancy. Fetal akinesia se-
quencewas detected on ultrasound at 19weeks of gestation
and the pregnancy was terminated at 23 weeks gestation.
Postmortem examination showed fetal dysmorphology
(micrognathia, low-set ears, a short nose, a short philtrum,
thin lips, and a short broad neck) and subcutaneous edema
of the head, neck, and shoulders (Figure 2C). The elbows
were abnormally ﬂexed, the wrists were hyperextended,
and the second and third digits overlapped on both hands.
No pterygia were identiﬁed. The lungs were hypoplastic.
Neuromuscular histopathological examination failed to
identify a speciﬁc underlying cause for the fetal akinesia.
The brain and spinal cord were normal on macroscopic
and microscopic examination. The muscle ﬁbers were of
normal diameter for gestational age. No abnormalities
were detected on enzyme analysis. On electronmicroscopy,
the striatedmuscle appearedwell developed. All three casesFigure 1. Sequence Traces for Normal Control, Homozygote, and Heterozygote Carrier of RAPSN Frameshift Mutationerican Journal of Human Genetics 82, 222–227, January 2008 223
showed occasional muscle ﬁbers with centrally located nu-
clei, but this appearancewas observed in<5%of themuscle
ﬁbers examined and was not diagnostic of a myotubular
dystrophy. The couple also have two healthy children.
Previously, mutations in AChR subunits have been
associated with congenital myasthenic syndromes (CMS).
These are a heterogeneous group of inherited disorders of
neuromuscular transmission characterized by fatiguable
muscle weakness. CMS affecting the AChR may alter
AChR channel kinetics or severely reduce the number of
AChRs in the postsynaptic membrane and can result
in AChR deﬁciency from mutations in CHRNA1, CHRNB1,
CHRND, or CHRNE.12,13 However, mutations in CHRNE
generally result in a mild phenotype, whereas AChR
deﬁciency mutations in CHRNA1, CHRNB1, and CHRND
are rare and more severe. Although the CMS phenotypes
Figure 2. Clinical Features of Fetal Akinesia Associated with
Homozygous Rapsyn Mutation
(A and B) Affected twin fetuses.
(C) Affected singleton fetus with clinical features of the fetal
akinesia sequence.224 The American Journal of Human Genetics 82, 222–227, Januaryare distinct from that of MPS, one CMS patient who was
a compound heterozygote for a mutation that gives rise
to fast-channel AChR kinetics and a null mutation in
CHRND had arthrogryposis.14
CMSmay also result frommutations in other postsynap-
tic proteins involved in neuromuscular transmission or
in the formation and maintenance of the neuromuscular
junction. Thus, recessive germline mutations in RAPSN
have been reported in patients with CMS and AChR deﬁ-
ciency.15–18 The RAPSN gene product (rapsyn, receptor-
associated protein of the synapse) has a key role in the clus-
tering of AChRs at the neuromuscular synapse.19 The most
frequent RAPSN mutation associated with CMS is the
founder p.N88K missense mutation that is thought to
have arisen in an ancient Indo-European population.20
Genotype-phenotype correlations have been described
forCMS-associatedRAPSNmutations, such that individuals
who are homozygous for a p.N88K disease have less severe
disease thancompoundheterozygoteswith a single p.N88K
allele.21 These observations suggested that p.N88K may
cause a less severe defect than mutations that produce
a truncated protein or altered membrane attachment. To
date, homozygosity (or compound heterozygosity) for mu-
tations in RAPSN predicted to cause a truncated protein
have not been described in CMS. The c.1177-1178delAA
mutation we identiﬁed was not detected in 340 control
chromosomes (140 in the current study and 200 reported
previously16) and has previously been reported (in combi-
nation with the p.N88K allele) in patients with CMS.
Affected patients had decreased fetal movements, ﬂexion
contractures, craniofacial anomalies, hypotonia, and inter-
mittent respiratory failure.16,22 We postulated that the
c.1177-1178delAA mutation caused a more severe deﬁcit
in rapsyn function than p.N88K and so homozygosity for
c.1177-1178delAA caused a fetal akinesia, rather than
a CMS phenotype. To test this hypothesis, the effect of
the c.1177-1178delAA mutation on rapsyn function was
investigated.
The c.1177-1178delAA mutation predicts a frameshift
after residue 392 of rapsyn resulting in 82 C-terminal mis-
sense amino acids (Figure 3A). Wild-type and mutant rap-
syn were tagged with EGFP in-frame at their C termini and
cotransfected with cDNAs encoding the human AChR into
the muscle cell line TE671. TE671 cells were maintained at
37C in DMEM (Sigma-Aldrich) supplemented with 10%
FCS (TCS Cellworks) and 100 units/ml each of penicillin
G and streptomycin (PS) purchased from Invitrogen. TE671
cells do not express detectable levels of endogenous rapsyn
polypeptide. After transfection, effects on AChR clustering
were studied. Thus, TE671 cells were seeded at 23 105 cells
per well on coverslips in 6-well plates and the following day
were transfected with a total of 3 mg DNA per well via cal-
cium phosphate precipitation. Amounts of DNA used per
well was 1 mg AChR a-subunit DNA, 0.5 mg each of AChR
b-, d-, and 3-subunit cDNA, and 0.5 mg of rapsyn cDNA or
pcDNA3.1-hygro for ‘‘no rapsyn’’ control transfections.
Transfections with only rapsyn and no AChR were carried2008
Figure 3. Functional Analysis of RAPSN Mutation Associated with Fetal Akinesia Sequence
(A) DNA sequences and translations of exon 8 for wild-type and mutant human rapsyn. In the wild-type sequence, the two nucleotides
that are deleted in the mutant are shown in red. As a consequence of the frameshift, mutant rapsyn is 62 amino acid residues longer than
wild-type (asterisk indicates termination codon).
(B) Diagram of wild-type and mutant rapsyn tagged with EGFP at the carboxyl terminus. Wild-type or mutant rapsyn cDNA without a stop
codon were cloned into pEGFP-N1 (Clontech) so that EGFP was in-frame with rapsyn. Mutagenesis to delete the two adenine residues was
carried out with the QuikChange mutagenesis kit purchased from Stratagene and was confirmed by DNA sequencing. The frameshift in the
c.1177-1178delAA mutant extends the length of the protein by 62 amino acid residues, and so the corresponding 30UTR was included in
this construct.
(C) Rapsyn mutation c.1177-1178delAA (also referred to as 1177delAA) does not cluster the AChR. TE671 cells were cotransfected with
cDNAs encoding rapsyn-EGFP or rapsyn-1177delAA-EGFP and the human AChR subunits. AChR was detected with mAb B3 directed against
the AChR b subunit.28 Cells were fixed with 3% paraformaldeyde at room temperature for 20 min, washed three times with PBS, and
incubated with secondary antibody Alexa Fluor 594 goat anti-mouse IgG (HþL) diluted 1:1000 in PBS containing 1% BSA (Molecular
Probes). Cells were washed 33 in PBS and mounted in fluorescent mounting media (Dako Cytomation). Microscopy was performed on
an Olympus BX60 wide-field fluorescence microscope, and images were captured with Openlab software (Improvision).
(D) Western blot of rapsyn-EGFP and rapsyn-1177delAA-EGFP expressed in TE671 muscle cells. TE671 cells were transfected with wild-type
or mutant rapsyn-EGFP, and 48 hr later, total cell lysate was analyzed by Western blotting. Rapsyn was detected by mAb clone 1234
(Abcam) followed by anti-mouse-HRP and ECL (Amersham). As a control, a-tubulin was detected on the same western blots with
a mAb (Sigma-Aldrich) followed by anti-mouse-HRP and ECL. The experiment was performed twice; one example is shown.
(E) The ratio of rapsyn:a-tubulin was obtained by densitometric scanning of western blots. Whereas rapsyn-EGFP gave robust expression
on days 1 and 2, rapsyn-1177delAA-EGFP was barely detectable throughout the time course.out with 3 mg/well of rapsyn expression plasmids. The next
day, the media was replaced with fresh medium. Whereas
transfection with wild-type rapsyn resulted in the colocal-
ization of rapsyn and AChR on the cell surface in small
dense clusters, transfection with rapsyn-392þ82-EGFP re-
sulted in low levels of EGFP ﬂuorescence within the cells
and unclustered AChR expressed uniformly along the cell
surface. To examine this observation further, we performed
a time course of rapsyn expression after transfection byThe Awestern blots on cell extracts. Conﬁrming the observation
fromﬂuorescencemicroscopy, themutant rapsynwas pres-
ent at much lower levels and by 3 days after transfection
could not be detected. The results suggest that the mutant
rapsyn is rapidlydegraded. It is likely that in thepatient fetal
AChR are not clustered because of the loss of rapsyn, which
results in the disruption of the neuromuscular synapse for-
mation and neuromuscular transmission, which in turn
results in severe fetal akinesia.merican Journal of Human Genetics 82, 222–227, January 2008 225
We found that homozygosity for a frameshift RAPSN
mutation that severely impaired protein stability was asso-
ciated with a fetal akinesia phenotype. Previously it was
reported that rapsyn missense mutations p.L361R and
p.N88K showed a partial loss of function with reduced
colocalization. Both mutations could effectively mediate
agrin-induced AChR clusters in myotubes but they were
less stable than clusters generated with wild-type rapsyn.23
This observation is consistent with the hypothesis that
RAPSN mutations may cause a spectrum of phenotypes
ranging from later onset (third decade) CMS with ‘‘mild
mutations’’ through neonatal CMS with arthrogryposis,
to fetal akinesia with lethality (homozygosity for severe
truncating mutations).24 The c.1177-1178delAA mutation
identiﬁed in our family had previously been reported in
CMS, although it is not knownwhether this represents a re-
current or founder mutation. Although the development
of neuromuscular junction differs in mice and men, the
phenotype of Chrng and Rapsn gene inactivation in mice
are similar. Thus, homozygous mutant transgenic mice
with targeted disruption of the Rapsn gene died within
hours of birth with respiratory insufﬁciency and profound
muscle weakness.25 The mutant mice neuromuscular junc-
tion showed no detectable AChR clusters along the length
of muscle ﬁbers. Together with the previous reports
of CHRNG in MPS, it suggests that functional AChR deﬁ-
ciency will be a signiﬁcant cause of MPS/fetal akinesia.5,6
Although we did not identify germline mutations in
CHRNA1, CHRNB1, and CHRND in our cohort of patients,
further analysis of these genes and of other genes impli-
cated in CMS, such as MUSK26 or DOK7,27 may further ex-
pand the role of defective signal transmission at the neuro-
muscular junction in the MPS/fetal akinesia sequence.
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